

**From:** Schwartz, Jack A [/O=ZENECA/OU=PHWILM/CN=RECIPIENTS/CN=SCHWARTZ]  
**Sent:** Monday, July 29, 2002 4:11 PM  
**To:** 'sumie\_ishiguro@po.fujisawa.co.jp'  
**Cc:** Brecher, Martin; Dev, Vikram J; Geller, Wayne; Melville, Margaret G; Nakajo, Hirochika  
**Subject:** FW: Effect of Seroquel on diabetes mellitus

Dear Ishiguro-san,

Per the attached, Melville-san asked that I repsond to your request. We should be able to provide the trial 41 glucose data to you by the end of August. I hope this date is in an acceptable time frame and that this information will help you with your labeling.

Best regards,

Jack Schwartz

-----Original Message-----

**From:** Sumie Ishiguro [mailto:sumie\_ishiguro@po.fujisawa.co.jp]  
**Sent:** Monday, July 29, 2002 3:02 AM  
**To:** Brecher, Martin  
**Cc:** Dev, Vikram J; Geller, Wayne; Melville, Margaret G; Higuchi Sadao  
**Subject:** Effect of Seroquel on diabetes mellitus


Dear Brecher-san,

How are you? Two months have passed since we held a meeting in Philadelphia. I'm sure everything must be going on well.

As you may already know, AZKK and F are working together to negotiate with the MHLW on revising the labeling of Seroquel. We came to an agreement by adding 'hyperglycemia' to "Other adverse reactions" as for the first revision. However, the MHLW is also indicating that we should discuss adding something about diabetes mellitus to 'Careful Administration' as soon as possible.

At the meeting in May, we discussed over the relationship of Seroquel and diabetes mellitus. You told us that clinical trial No.41 would be finished at the end of July, and the data of the trial would be useful when considering the effect of Seroquel on fasting blood sugar.

If the results turn out that Seroquel doesn't have any effect on fasting blood sugar, it would be an encouraging evidence on revising the labeling. So if you have already gone through the data and reached to some conclusions, I would really appreciate it if you would let me know them. But, if you haven't got the data yet, please let me know when you are expecting to get them.



Best regards,  
Sumie Ishiguro

\*\*\*\*\*

Sumie Ishiguro  
FUJISAWA PHARMACEUTICAL CO., LTD.  
Post-marketing Surveillance I  
TEL:+81-6-6390-2386□\$B!!□(JFAX:+81-6-6304-1319

\*\*\*\*\*